Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

Returns on capital

Werewolf Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-245.2%

avg -83.0%

ROIC

-173.4%

avg -58.1%

ROA

-87.6%

avg -41.7%

Analysis

ROA is currently the strongest return metric at -87.6% versus its period average of -41.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel J. Hicklin

Founder, CEO, President & DirectorUSD 645.56K62185.65K0.38%

Jonathan Owen

Senior VP, General Counsel & Secretary————

Michael Urban

VP of Finance, Corporate Controller & Principal Financial Officer—45——

Compensation is shown in the reported currency; data updated Oct 19, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 2, 2025.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

112

$4.37M

Net Transaction Value

−$4.37M

Net selling

Most Active

EVNIN LUKE

70 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 7, 26

EVNIN LUKE

Indirect

Sell$33.3K
Jul 6, 26

EVNIN LUKE

Indirect

Sell$11.4K
Jun 29, 26

EVNIN LUKE

Indirect

Sell$47.1K
Jun 17, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$136.2K
Jun 17, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$9.7K
Jun 16, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$51.7K
Jun 16, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$3.7K
Jun 15, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$46.9K
Jun 15, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$3.3K
Jun 12, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$63.6K

1–10 of 112

Summary

Insiders reported 0 buys worth $0.00 and 112 sells worth $4.37M over the last 12 months. That adds up to net selling of $4.37M. EVNIN LUKE was the most active insider with 70 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Werewolf Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about HOWL's management, answered from reported figures.

Who manages HOWL?

Werewolf Therapeutics, Inc. (HOWL) lists 3 active executives. The top listed executive is Daniel J. Hicklin, Founder, CEO, President & Director.

Are HOWL insiders buying or selling?

Recent insider activity shows net selling of $5.39M.